Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder

S. Fehr, K. Wong, R. Chin, S. Williams, Nicholas De Klerk, David Forbes, R. Krishnaraj, J. Christodoulou, J. Downs, H. Leonard

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

© 2016 American Academy of Neurology.Objective: To investigate seizure outcomes and their relationships to genotype and functional abilities in individuals with the cyclin-dependent kinase-like-5 (CDKL5) disorder. Methods: Using the International CDKL5 Disorder Database, we identified 172 cases with a pathogenic CDKL5 mutation. We categorized individual mutations into 4 groups based on predicted structural and functional consequences. Negative binomial regression was used to model the linear association between current seizure rate and mutation group, current level of assistance required to walk 10 steps, and the highest level of expressive communication used to convey refusal or request. Results: All but 3 (169/172) patients had a history of epilepsy. The median age at seizure onset was 6 weeks (range 1 week-1.5 years) and the median seizure rate at ascertainment was 2 per day (range 0-20 per day). After adjusting for walking ability and confounders including use or otherwise of polytherapy, seizure rate was lower in those with truncating mutations between aa172 and aa781 compared to those with no functional protein (incidence rate ratio [IRR] 0.57; 95% confidence interval [CI] 0.35-0.93). Ability to walk and use of spoken language were associated with lower rates of current seizures when compared to those with the least ability after adjusting for genotype (walking: IRR 0.62; 95% CI 0.39-0.99, communication: IRR 0.48; 95% CI 0.23-1.02). At a median age at questionnaire completion of 5 years, those previously treated with corticosteroids had more frequent seizures than those who have never been treated, whether or not there was a history of infantile spasms. Conclusions: Epilepsy is pervasive but not mandatory for the CDKL5 disorder. Genotype and functional abilities were related to seizure frequency, which appears refractory to antiepileptic drugs.
Original languageEnglish
Pages (from-to)2206-2213
JournalNeurology
Volume87
Issue number21
DOIs
Publication statusPublished - 2016

Fingerprint

Cyclin-Dependent Kinase 5
Aptitude
Seizures
Genotype
Confidence Intervals
Mutation
Walking
Epilepsy
Incidence
Communication
Infantile Spasms
Mutation Rate
Age of Onset
Anticonvulsants
Linear Models
Adrenal Cortex Hormones
Language
Databases

Cite this

Fehr, S. ; Wong, K. ; Chin, R. ; Williams, S. ; De Klerk, Nicholas ; Forbes, David ; Krishnaraj, R. ; Christodoulou, J. ; Downs, J. ; Leonard, H. / Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder. In: Neurology. 2016 ; Vol. 87, No. 21. pp. 2206-2213.
@article{9092f56c5be047cdb2e39649667aee7d,
title = "Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder",
abstract = "{\circledC} 2016 American Academy of Neurology.Objective: To investigate seizure outcomes and their relationships to genotype and functional abilities in individuals with the cyclin-dependent kinase-like-5 (CDKL5) disorder. Methods: Using the International CDKL5 Disorder Database, we identified 172 cases with a pathogenic CDKL5 mutation. We categorized individual mutations into 4 groups based on predicted structural and functional consequences. Negative binomial regression was used to model the linear association between current seizure rate and mutation group, current level of assistance required to walk 10 steps, and the highest level of expressive communication used to convey refusal or request. Results: All but 3 (169/172) patients had a history of epilepsy. The median age at seizure onset was 6 weeks (range 1 week-1.5 years) and the median seizure rate at ascertainment was 2 per day (range 0-20 per day). After adjusting for walking ability and confounders including use or otherwise of polytherapy, seizure rate was lower in those with truncating mutations between aa172 and aa781 compared to those with no functional protein (incidence rate ratio [IRR] 0.57; 95{\%} confidence interval [CI] 0.35-0.93). Ability to walk and use of spoken language were associated with lower rates of current seizures when compared to those with the least ability after adjusting for genotype (walking: IRR 0.62; 95{\%} CI 0.39-0.99, communication: IRR 0.48; 95{\%} CI 0.23-1.02). At a median age at questionnaire completion of 5 years, those previously treated with corticosteroids had more frequent seizures than those who have never been treated, whether or not there was a history of infantile spasms. Conclusions: Epilepsy is pervasive but not mandatory for the CDKL5 disorder. Genotype and functional abilities were related to seizure frequency, which appears refractory to antiepileptic drugs.",
author = "S. Fehr and K. Wong and R. Chin and S. Williams and {De Klerk}, Nicholas and David Forbes and R. Krishnaraj and J. Christodoulou and J. Downs and H. Leonard",
year = "2016",
doi = "10.1212/WNL.0000000000003352",
language = "English",
volume = "87",
pages = "2206--2213",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams & Wilkins",
number = "21",

}

Fehr, S, Wong, K, Chin, R, Williams, S, De Klerk, N, Forbes, D, Krishnaraj, R, Christodoulou, J, Downs, J & Leonard, H 2016, 'Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder' Neurology, vol. 87, no. 21, pp. 2206-2213. https://doi.org/10.1212/WNL.0000000000003352

Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder. / Fehr, S.; Wong, K.; Chin, R.; Williams, S.; De Klerk, Nicholas; Forbes, David; Krishnaraj, R.; Christodoulou, J.; Downs, J.; Leonard, H.

In: Neurology, Vol. 87, No. 21, 2016, p. 2206-2213.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder

AU - Fehr, S.

AU - Wong, K.

AU - Chin, R.

AU - Williams, S.

AU - De Klerk, Nicholas

AU - Forbes, David

AU - Krishnaraj, R.

AU - Christodoulou, J.

AU - Downs, J.

AU - Leonard, H.

PY - 2016

Y1 - 2016

N2 - © 2016 American Academy of Neurology.Objective: To investigate seizure outcomes and their relationships to genotype and functional abilities in individuals with the cyclin-dependent kinase-like-5 (CDKL5) disorder. Methods: Using the International CDKL5 Disorder Database, we identified 172 cases with a pathogenic CDKL5 mutation. We categorized individual mutations into 4 groups based on predicted structural and functional consequences. Negative binomial regression was used to model the linear association between current seizure rate and mutation group, current level of assistance required to walk 10 steps, and the highest level of expressive communication used to convey refusal or request. Results: All but 3 (169/172) patients had a history of epilepsy. The median age at seizure onset was 6 weeks (range 1 week-1.5 years) and the median seizure rate at ascertainment was 2 per day (range 0-20 per day). After adjusting for walking ability and confounders including use or otherwise of polytherapy, seizure rate was lower in those with truncating mutations between aa172 and aa781 compared to those with no functional protein (incidence rate ratio [IRR] 0.57; 95% confidence interval [CI] 0.35-0.93). Ability to walk and use of spoken language were associated with lower rates of current seizures when compared to those with the least ability after adjusting for genotype (walking: IRR 0.62; 95% CI 0.39-0.99, communication: IRR 0.48; 95% CI 0.23-1.02). At a median age at questionnaire completion of 5 years, those previously treated with corticosteroids had more frequent seizures than those who have never been treated, whether or not there was a history of infantile spasms. Conclusions: Epilepsy is pervasive but not mandatory for the CDKL5 disorder. Genotype and functional abilities were related to seizure frequency, which appears refractory to antiepileptic drugs.

AB - © 2016 American Academy of Neurology.Objective: To investigate seizure outcomes and their relationships to genotype and functional abilities in individuals with the cyclin-dependent kinase-like-5 (CDKL5) disorder. Methods: Using the International CDKL5 Disorder Database, we identified 172 cases with a pathogenic CDKL5 mutation. We categorized individual mutations into 4 groups based on predicted structural and functional consequences. Negative binomial regression was used to model the linear association between current seizure rate and mutation group, current level of assistance required to walk 10 steps, and the highest level of expressive communication used to convey refusal or request. Results: All but 3 (169/172) patients had a history of epilepsy. The median age at seizure onset was 6 weeks (range 1 week-1.5 years) and the median seizure rate at ascertainment was 2 per day (range 0-20 per day). After adjusting for walking ability and confounders including use or otherwise of polytherapy, seizure rate was lower in those with truncating mutations between aa172 and aa781 compared to those with no functional protein (incidence rate ratio [IRR] 0.57; 95% confidence interval [CI] 0.35-0.93). Ability to walk and use of spoken language were associated with lower rates of current seizures when compared to those with the least ability after adjusting for genotype (walking: IRR 0.62; 95% CI 0.39-0.99, communication: IRR 0.48; 95% CI 0.23-1.02). At a median age at questionnaire completion of 5 years, those previously treated with corticosteroids had more frequent seizures than those who have never been treated, whether or not there was a history of infantile spasms. Conclusions: Epilepsy is pervasive but not mandatory for the CDKL5 disorder. Genotype and functional abilities were related to seizure frequency, which appears refractory to antiepileptic drugs.

U2 - 10.1212/WNL.0000000000003352

DO - 10.1212/WNL.0000000000003352

M3 - Article

VL - 87

SP - 2206

EP - 2213

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 21

ER -